Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy, a Randomised Phase II Parallel Cohort Trial
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms POPSTAR II
Most Recent Events
- 11 Jul 2025 Planned End Date changed from 1 May 2026 to 1 May 2027.
- 11 Jul 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.
- 13 Dec 2023 Status changed from not yet recruiting to recruiting.